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Summary and Key Points 
1. Tobacco is the leading cause of lung cancer. Radon exposure in the 
air over time is a second, but distant leading cause. Asbestos 
exposure, especially when combined with tobacco use, is a cause of 
mesothelioma. 
2. The two major pathology categories of lung cancer are non-small cell 
lung cancer and small cell lung cancer. Common types of non-small 
cell lung cancers are adenocarcinoma, squamous cell and large cell 
carcinoma. Mesothelioma is a cancer of the pleura. 
3. Treatment of lung cancer and mesothelioma requires a 
multidisciplinary approach to care involving Medical Oncologists, 
Radiation Oncologists, Thoracic Surgeons, Pulmonologists, Palliative 
Care Physicians, Pathologists, Radiologists, and Primary Care 
Physicians. 
4. The foundation for the curative treatment of early stage non-small 
cell lung cancer and mesothelioma is surgery. 
5. The foundation for the curative treatment of early stage small cell 
carcinoma of the lung is combination chemoradiotherapy, although a 
few patients with very early small cell lung cancer may benefit from 
resection of the primary. 
6. The goal of treatment for early stage non-small cell lung cancer and 
some presentations of limited stage small cell lung cancer is cure. 
7. Small cell lung cancers and advanced stage non-small cell lung 
cancers are treated with systemic therapy (such as chemotherapy or 
biologic therapy). 
8. Chemotherapy with or without radiation therapy is used to treat 
unresectable or advanced stage mesothelioma. 
9. When cure is not possible, improvement in quality of life is the 
important goal regardless of whether there is an increase in the 
quantity of life gained from treatment (although sometimes, the latter 
is achieved). 
Introduction 
Lung cancer (non-small cell and small cell carcinomas) includes 
malignancies that arise within the lung parenchyma or bronchi. The 
pleural surface of the lungs gives rise to mesothelioma. Lung cancers 
are pathologically categorized into non-small cell and small cell 
carcinoma. Surgery, chemotherapy, and radiation therapy all play 
important roles in the treatment of lung cancer. There is an exciting and 
developing understanding of the wide variety of biologic characteristics 
and behaviors of lung cancers and new biologic and molecular tests 
have enabled clinicians to better tailor individualized treatment 
strategies. 
Epidemiology 
The American Cancer Society has estimated that in 2009, there were 
219,440 new diagnoses of lung cancer and 159,390 deaths from the 
disease in the United States. Lung cancer is the second most common 
form of cancer in both men and women. It remains the most common 
cause of cancer-related death. Lung cancer incidence in the United 
States climbed throughout the 20th century as tobacco smoking became 
increasingly popular. Rates of smoking among men began to fall in the 
1960’s and, beginning in the early 1990’s, the incidence rate of lung 
cancer in men also began to fall. Rates of smoking among women were 
never as high as those in men. However, decline in smoking rates 
among women did not begin until the 1970’s. The lung cancer incidence 
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rate among women peaked in the 1990’s and there has been little 
reduction in the rate since then. 
There are about 2500 cases of mesothelioma diagnosed each year in 
the United States. The Surveillance, Epidemiology, and End Results 
(SEER) data base reports that the incidence of mesothelioma peaked in 
the early 1990’s, and has been gradually declining since. The peak and 
decline in mesothelioma incidence is believed to be due to the 
widespread use of asbestos in construction during the 20th century. Since 
the early 1970’s however, federal regulations have sharply limited the 
use of asbestos. 
Etiology 
In the United States and around the world, cigarette smoking is the 
strongest and most prevalent risk factor for the development of lung 
cancer. The risk is related not only to the amount of cigarette use 
(usually expressed as packs per day) but to the cumulative duration of 
such use (usually expressed as pack years). Cigarette use is estimated 
to account for approximately 90% of all lung cancers. Thus, it is a readily 
targeted life style risk factor. Second hand smoke exposure (and some 
people believe even third hand exposure from carcinogens that deposit 
on clothing) is a real risk factor, albeit nowhere near as significant as first 
hand exposure. 
The role that genetics play in the etiology of lung cancer is not clear. 
There are people who develop lung cancer without any known cigarette 
use or other risk factors. In addition, not all people who smoke cigarettes 
develop lung cancer. There are some familial genetic syndromes, but 
these are not common. 
In the last half century, the relative incidence of squamous cell 
carcinoma has fallen compared to adenocarcinoma. It is believed that 
this change in histology is in large part due to the wide-spread 
introduction of filtered cigarettes in the 1950’s. Though the overall risk of 
lung cancer from filtered cigarettes is the same as from unfiltered 
cigarettes, filters alter the type of carcinogens and location of carcinogen 
deposition resulting from smoking. Filters force smokers to inhale more 
deeply, increasing the likelihood that carcinogens will be deposited deep 
in alveoli or terminal bronchioles. This altered pattern of carcinogen 
deposition has been hypothesized to be the reason why the usually 
peripherally-based adenocarcinomas have been increasing in frequency 
as compared to the usually centrally-based squamous cell carcinomas in 
the last two decades. Deeper inhalation also results in hotter and more 
complete combustion of the cigarette. 
Risk factors for the development of mesothelioma include asbestos 
exposure and cigarette smoking. The combination of the two multiplies 
the risk. Shipyard workers, plumbers, construction-workers and asbestos 
miners were at significant risk of asbestos exposure. Occupational 
history is an important part of the workup for mesothelioma. 
Screening 
Recently, the National Lung Screening Trial (NLST) demonstrated 
decreased mortality in high risk patients (patients 55-74 years of age with 
a 30 pack-year smoking history who were currently smoking (or quit 
within the previous 15 years) who underwent low dose chest CT scan to 
screen for lung cancer. These results are encouraging and low dose 
radiation CT screening of patients at high risk for lung cancer has now 
been endorsed by a number of national organizations. However, 
associated harms include radiation exposure, false positive results, and 
unnecessary interventions (Figure 1). 
 
Figure 1. 74 year old woman with a 50 plus tobacco year history quitting in 2007. 
PFT’s in 2013 revealed a moderate-severe obstructive ventilatory defect. CT 
shows a suspicious 2.3 cm ground glass opacity in the right lower lobe. This may 
represent a small focus of pneumonia or a primary lung cancer such as minimally 
invasive adenocarcinoma. This lesion persisted on follow-up imaging favoring the 
diagnosis of a carcinoma. Image courtesy of the University of Massachusetts 
Medical School, Department of Radiology. 
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Recommendation 
The United States Public Health Service Task Force on Prevention 
recommendations are summarized below: 
• Asymptomatic adults aged 55 to 80 years who have at least a 30 
pack-year smoking history and currently smoke or have quit 
smoking within the past 15 years. Screen annually for lung cancer 
with low-dose computed tomography. 
• Discontinue screening when the patient has not smoked for 15 
years (Figure 2). 
 
Figure 2. 53 year old woman, with significant tobacco history, referred for 
screening. 3.1 cm left upper lobe mass (blue arrow), 1.2 cm right upper lobe 
nodule (red arrow), and 2.6 cm right lower lobe nodule (green arrow) were found, 
concerning for malignancy. The spiculated appearance of all 3 lesions suggests 
synchronous primary lung cancers. Image courtesy of the University of 
Massachusetts Medical School, Department of Radiology. 
It is important to appreciate that the vast majority of lung nodules 
identified by CT screening are not cancer. The costs and risks to patients 
of evaluating many benign lung nodules will have to be weighed against 
potential benefits of screening for each patient. Additionally, the NLST 
was conducted in a limited number of centers with a well-defined 
protocol for evaluating lung nodules. Any screening program based on 
the NLST should incorporate the same rigorous standards that were 
used in the study. 
Clinical Presentation 
A majority of lung cancers are diagnosed at advanced stages. This is 
due in part to the limitations of screening for lung cancer and to lung 
cancer developing in a stealthy manner, often being asymptomatic at 
early stages of the disease. In addition, a number of presenting 
symptoms (cough, shortness of breath, weight loss, decreased appetite, 
and fatigue) are nonspecific and can be caused by a variety of other non-
malignant etiologies, most often pneumonia (Figures 3a & b). 
 
Figure 3a. Chest X-ray demonstrates an opacity in the right lower lobe. The right 
hilum is biconvex & masslike in shape. This finding is suggestive of post-
obstructive pneumonia versus pneumonia with reactive lymphadenopathy Image 
courtesy of the University of Massachusetts Medical School, Department of 
Radiology. 
 
Figure 3b. AP Digital Reconstructed Radiograph (DRR) (from CT scan) Lung 
window, better defines the consolidation in the right lower lobe than the chest 
xray. Image courtesy of the University of Massachusetts Medical School, 
Department of Radiology. 
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Sometimes hemoptysis (coughing up of blood), pain, hoarseness, 
dysphagia (difficulty swallowing), and other systemic symptoms are 
present at the time of diagnosis. 
In any person who smokes cigarettes, has been a cigarette user, or has 
other identifiable risk factors, the above symptoms should indicate the 
need to obtain imaging of the lungs (usually one begins with a chest x-
ray (Figure 6a) and then subsequently can employ more detailed 
imaging studies such as computed tomography (CT) (Figures 3c & d; 4a 
& b) and positron emission tomography (PET) scans (Figure 5). 
 
Figures 3c & 3d. Lung window ????- Shows the pneumonia in the right lower 
lobe. Mediastinal window ????- Demonstrates a nodule as the cause of the post-
obstructive pneumonia (arrow). Further work up confirms lymphoma in this 
patient. Image courtesy of the University of Massachusetts Medical School, 
Department of Radiology. 
 
 
Figure 4a. Adenocarcinoma. AP and lateral views of the chest demonstrates a 
large mass-like opacity occupying the left lower lobe Image courtesy of the 
University of Massachusetts Medical School, Department of Radiology. 
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Figure 4b. Adenocarcinoma. Axial and coronal images of chest CT confirm the 
presence of a large mass within the left lung (red arrow). A large necrotic 
contralateral lymph node was noted (blue arrow). Biopsy proved the mass to be 
adenocarcinoma. This patient has Stage T3 N3 disease by chest CT criteria. 
Image courtesy of the University of Massachusetts Medical School, Department 
of Radiology. 
 
Figure 5. Squamous cell carcinoma. Frontal view of the chest demonstrates 
round lesion with lucency in the right upper lobe concerning for a cavitary tumor 
which is better seen on the coronal and axial views of the contrast enhanced CT 
of the chest. PET shows intense tracer uptake correlates with the right upper 
lobe cavitary lesion and is consistent with biopsy proven squamous cell 
carcinoma. Squamous cell carcinomas tend to cavitate. Notice 2 smaller areas of 
increased PET positivity consistent with hilar and mediastinal nodal disease. So 
this patient has T2a N2 disease by PET criteria. Image courtesy of the University 
of Massachusetts Medical School, Department of Radiology. 
Pathology 
There are two major pathology categories of lung cancer (excluding 
mesothelioma): non-small cell and small cell. Within the non-small cell 
category, the common pathology designations include adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma 
(Figure 6) accounts for approximately 40% of lung cancers, squamous 
cell carcinoma (Figure 7) approximately 25%, large cell (Figure 9) 
approximately 10% and small cell cancer (Figure 8) approximately 15%. 
Miscellaneous other pathologies make up about 10% of cases. 
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Figure 6. The malignant cells in adenocarcinoma are composed of 
cuboidal or columnar shaped cells either growing along the alveolar walls 
(as illustrated here) or showing glandular proliferation. The malignant cells 
have hyperchromatic nuclei with prominent nucleoli and eosinophilic 
cytoplasm with or without mucin. Image courtesy of the University of 
Massachusetts Medical School, Department of Pathology. 
Squamous Cell Carcinoma 
 
Figure 7. The malignant cells in squamous cell carcinoma show keratinization 
and /or intercellular bridges. Keratinization could be manifested as either keratin 
pearl formation (as illustrated here) and/or individual cells with markedly 
eosinophilic dense cytoplasm. Image courtesy of the University of Massachusetts 
Medical School, Department of Pathology. 
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Small Cell Carcinoma 
 
Figure 8. The malignant cells in small cell carcinoma are small and densely 
packed with scant cytoplasm, indistinct cytoplasmic borders, finely granular 
nuclear chromatin and absent or inconspicuous nucleoli. Hematoxylin has a deep 
blue-purple color and stains nucleic acids whereas Eosin stains proteins, which 
are mostly found in the cytoplasm. The malignant cells in small cell carcinoma 
have very little cytoplasm and are densely packed. Therefore, they would look 
more purple on Hematoxylin and Eosin stains Image courtesy of the University of 
Massachusetts Medical School, Department of Pathology. 
Large Cell Carcinoma 
 
Figure 9. ??. Large cell carcinoma 100X: The neoplasm is comprised of diffuse 
sheets of malignant cells without morphologic evidence of squamous and 
glandular differentiation. Portion of normal lung parenchyma is also present in the 
lower left corner of the picture. 
??? Large cell carcinoma 400X: Large vesicular nuclei with prominent nucleoli and 
abundant clear or eosinophilic cytoplasm are noted on malignant cells. No keratin 
pearls, intercellular bridges, mucin or gland formation are seen. A few mitotic 
figures are also present in this field. Image courtesy of the University of 
Massachusetts Medical School, Department of Pathology. 
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Mesothelioma 
Mesothelioma (Figure 10a, b & c) is distinct from parenchymal lung 
cancer. It arises from the pleural surface that surrounds the lungs, 
whereas lung cancer arises from either the parenchymal tissues or the 
airways (although lung cancer can invade into or spread to the pleural 
surfaces). Three histologic types of malignant mesothelioma exist: 
epithelioid, sarcomatoid and biphasic (mixed epithelioid and 
sarcomatoid). 
 
Figure 10a. Epithelioid mesothelioma 40x magnification. The tumor is comprised 
of epithelioid cells that form nests and tubule-like structures infiltrating the 
subpleural adipose tissue (on the right). Image courtesy of the University of 
Massachusetts Medical School, Department of Pathology. 
 
 
Figure 10b. Epithelioid mesothelioma 100x magnification. Individual tumor cells 
have round vesicular nuclei with irregular borders and prominent nucleoli and 
esonophilic cytoplasm. Increased number of mitotic figures, including an atypical 
one (arrow), are seen within the tumor. The tumor cells are positive for 
mesothelial differentiation markers such as calretinin and WT-1 by 
immunohistochemistry. Image courtesy of the University of Massachusetts 
Medical School, Department of Pathology. 
 
Figure 10c. Epithelioid mesothelioma 400x magnification. Image ccourtesy of the 
University of Massachusetts Medical School, Department of Pathology. 
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Prognostic Factors, Staging and Natural History 
Lung cancer is staged with the American Joint Committee on Cancer 
(AJCC) tumor, lymph node, and metastasis (TNM) system, seventh 
edition. As with all cancers, staging is based on prognostic grouping and 
predicted natural history of the disease. So stage is a measure of an 
individual patient’s prognosis. The other important prognostic factor is 
the individual patient’s overall condition, referred to as Performance 
Status. 
Small cell lung cancer has a higher propensity to spread to distant parts 
of the body (metastasize) early in the course of the disease than does 
non-small cell lung cancer. However, any lung cancer can metastasize. 
The common anatomic locations for metastases include, but are not 
limited to, other parts of the lungs, regional lymph nodes, liver, adrenal 
glands (Figure 11), brain (Figure 12), and bones. Lung cancer can 
spread to the lymph nodes that are within and outside of the lungs, such 
as to the lung hilar areas, the mediastinum (the area in between the 
lungs), and to the supraclavicular regions (above the collar bones). Lung 
cancer can also grow by direct extension into nearby anatomic 
structures, such as the airways, the major blood vessels, the heart, and 
the chest wall. 
 
Figure 11. Metastasis to adrenal. 11a. Small spiculated mass (arrow) in the left 
upper lobe concerning for a primary lung cancer. 11b. Axial image at the level of 
right adrenal gland demonstrates a large soft tissue mass consistent with 
metastatic disease to the adrenal gland. Patient has Stage IV, T1 Nx M1 disease. 
Images courtesy of University of Massachusetts Medical School, Department of 
Radiology. 
 
Figure 12. 55 year old woman with 30 pack year smoking history was found to 
have a 3 cm right middle lobe carcinoma with spread to mediastinal lymph nodes 
and metastasis to the adrenal gland. No neurologic symptoms, but on routine 
staging brain MRI multiple small brain metastases are noted. 
???? Axial FLAIR image shows abnormal foci of hyperintensity at the grey-white 
junctions of the left frontal and left parietal lobes (blue circles) representing 
edema from tumor metastasis in these regions. 
???. Axial FLAIR image shows another abnormal focus of hyperintensity in the 
left superior frontal lobe representing edema related to a tiny metastasis in this 
region. In the right superior frontal lobe, there is another lesion with central 
hypointensity representing an area of central necrosis of a tumor. 
???? Post contrast axial T1 image demonstrates ring-enhancement of the right 
frontal tumor. Lack of internal enhancement is due to central necrosis. The left 
parietal metastasis is identified as a tiny punctate focus of enhancement 
indicating the actual size of the microscopic metastasis. Images courtesy of the 
University of Massachusetts Medical School, Department of Radiology. 
Mesothelioma has a lower tendency to metastasize than do most lung 
cancers. It is more apt to grow along the pleural surfaces and to extend 
directly into the lung parenchyma and the chest wall. It can also grow 
into the diaphragms, which sit underneath the lungs (Figures 13 & 14). 
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Figure 13. Chest x-ray demonstrating mesothelioma. Large mass in the right 
chest compressing the remaining pneumotized right upper lung with mild 
displacement of mediastinal structures to the left. Images courtesy of the 
University of Massachusetts Medical School, Department of Radiology. 
 
Figure 14. CT scan demonstrating mesothelioma. 14a. Mediastinal window 14b. 
Lung window. Images courtesy of the University of Massachusetts Medical 
School, Department of Radiation Oncology. 
Both lung cancer and mesothelioma can cause pleural effusions, which 
are collections of fluid within the pleural space that separates the lungs 
from the chest walls. As this pleural fluid expands, it compresses the 
lungs, adversely affecting lung function (producing shortness of breath). 
Pericardial fluid can also develop within the space between the heart and 
its surrounding lining (the pericardium). As this pericardial effusion 
grows, it compresses the rhythmic contraction of the heart and thereby 
diminishes cardiac function. This is referred to as cardiac tamponade, 
which can be life threatening. 
The presence of lymph node involvement by lung cancer (Figure 15) and 
the presence of any distant metastases are very important in staging 
lung cancer. The staging of lung cancer not only helps to identify 
appropriate treatment options, but also provides meaningful prognostic 
information as to the benefits of available therapies and prognosis. Non-
small cell lung cancer is staged based on the role that surgery may have 
in its treatment: early stage (surgery has a role), locally advanced stage 
(surgery may or may not have a role), and advanced stage (surgery does 
not have a role except for palliation). Starting in 2010, small cell cancers 
are staged with the same system as non-small cell cancers. The current 
lung staging systems can be found at The American Joint Committee on 
Staging and the revised TNM Staging System. 
Drawing a sketch of the extent of disease on a diagram of the body or 
the chest helps students learn staging systems and oncologists 
conceptualize the patient’s disease to plan appropriate treatment. These 
staging diagrams make the staging systems much clearer to physicians, 
by illustrating the extent of disease often clarifying treatment decisions 
and assist in learning the AJCC staging system for each disease site. 
An interactive series of staging diagrams are available here. 
 
Figure 15. Lymph node metastases. Double arrow- AP window node (ipsilateral, 
N2) Single arrow- Contralateral paratracheal node (N3) Image courtesy of the 
University of Massachusetts, Department of Radiology. 
Lung Cancer and Mesothelioma 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (28 December 2015) 
11 
Small cell lung cancer (Figures 16 & 17) now is staged with the same 
system as non-small cell cancer. The staging system previously used for 
this disease revolved around the role that radiation therapy could have in 
its treatment. If the extent of the tumor could be safely encompassed 
within a standard radiation field, then the small cell lung cancer was 
termed limited stage. Otherwise, the disease was called extensive stage, 
usually metastatic. This terminology is still found in older charts and 
academic papers, and in the minds of many oncologists. 
 
Figure 16. Small cell lung cancer 100X: Small cell carcinoma of lung showing 
diffuse sheets of small blue cells completely replacing lung parenchyma. Image 
courtesy of the University of Massachusetts, Department of Pathology. 
 
Figure 17. Small cell lung cancer 400X: On high magnification, the tumor is 
comprised of neoplastic cells showing nuclear molding, nuclei with salt-pepper 
chromatin and inconspicuous to absent nucleoli. There is a very high nuclei to 
cytoplasm ratio with only very scant rim of eosinophilic cytoplasm. The tumor 
reveals very high proliferative index as demonstrated with several mitotic figures 
in this field. Image courtesy of the University of Massachusetts, Department of 
Pathology. 
Imaging 
Common imaging studies used in the staging of lung cancer include CT, 
fluorodeoxyglucose positron emission tomography (FDG-PET), (Figures 
18a - c & Movie 1) magnetic resonance imaging (MRI), and radiolabeled 
technetium bone scan (Figure 19). There is no standard serum blood test 
used to diagnose lung cancer or mesothelioma. A number of serum 
markers have been identified, such as carcinoembryonic antigen (CEA), 
but as of now, they are not routinely used to screen for or to diagnose 
lung cancer. The key to proper diagnosis remains obtaining adequate 
tissue through a biopsy or from an operation for detailed pathology 
testing. There is a developing array of molecular and histochemical tests 
being used to aid in the diagnosis of lung cancer and mesothelioma. 
Increasingly, some molecular tests are also affecting treatment choices. 
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Figure 18a. CT and PET slice demonstrating a hypermetabolic lymph node in 
the left supraclavicular region representing a metastasis. Image courtesy of the 
University of Massachusetts, Department of Radiology. 
 
Figure 18b. CT and PET slice demonstrating a large mass in the left upper lobe. 
Pathology confirmed the diagnosis as adenocarcinoma. Image courtesy of the 
University of Massachusetts, Department of Radiology. 
 
Figure 18c. Matched CT and PET scan slices demonstrates a mass adjacent to 
the right ventricle, which does have increased uptake on the PET, representing 
either an enlarged lymph node or a myocardial appendage. Image courtesy of 












Movie 1. Axial slices of a PET scan of a lung cancer patient from cephalad to 
caudad, presented as a movie. Movie courtesy of the University of 
Massachusetts, Department of Radiology, Division of Nuclear Medicine. 
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Figure 19. Positive bone scan, showing metastases from lung cancer. Notice 
increased uptake of radiotracer in right proximal humerus, left acetabulum, 
sternum, multiple vertebrae, left scapula and sacrum. Image courtesy of the 
University of Massachusetts, Department of Radiology Division of Nuclear 
Medicine. 
Principles of Treatment 
A thorough history and physical examination are important to help 
identify the panoply of presenting problems and to identify any anatomic 
findings suggestive of cancer spread or anatomic compromise. Because 
most people who develop lung cancer have a cigarette smoking history, 
one needs to identify any other tobacco-related problems, such as 
coronary heart disease, diabetes mellitus, peripheral vascular disease, 
other cancers, emphysema, and central nervous problems (such as 
strokes). These medical issues can complicate and limit the treatment 
options available. 
Surgery 
For non-small cell lung cancer, surgical resection is the only reliable 
curative modality for patients who present at an early enough stage, 
which is unfortunately the minority. Lobectomy (Figures 20 and 21) is the 
surgery of choice for small to medium-sized tumors while 
pneumonectomy is done for larger or centrally located tumors. 
 
Figure 20. Lobectomy specimen. Courtesy of the University of Massachusetts, 
Department of Pathology. 
 
Figure 21. Lung adenocarcinoma in a lobectomy specimen forming a mass (4.7 
cm) and invading pleura. Courtesy of the University of Massachusetts, 
Department of Pathology. 
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Sublobar resection, either wedge resection, (Figure 22) or 
segmentectomy (Figure 23) is an acceptable alternative for peripheral 
Stage 1A tumors less than 2cms if a lobectomy (Figure 24) cannot be 
tolerated or is declined. 
 
Figure 22. Lung Wedge Resection, Right Upper Lobe. Illustration  
by Sarah Alyssa Uy. 
 
Figure 23. Apical Segmentectomy, Right Upper Lobe. Illustration  
by Sarah Alyssa Uy. 
 
Figure 24. Right Upper Lobectomy. Illustration by Sarah Alyssa Uy. 
An operation treats only localized disease, so if there is a higher 
likelihood of systematic metastases, chemotherapy is added after 
surgery. This is the case after selected Stage 1B and all Stage 2 
patients. For Stage 3 patients, there is a very high likelihood of systemic 
metastases in addition to extensive local disease so the foundation of 
treatment is a combination of radiation and chemotherapy, and in 
selected patients surgical resection is done afterwards to remove 
residual disease. The role of surgery in advanced or overtly metastatic 
disease is palliation, such as drainage of pleural effusion or relief of 
airway obstruction. 
For small cell lung cancer, surgical resection is not standard and is done 
only for selected patients with tumors smaller than 2cms with no lymph 
node metastases, and either preceded or followed by chemotherapy 
because of the great tendency of small cell cancer to metastasize early. 
The only form of surgery acceptable for these patients is lobectomy. The 
currently preferred treatment method, however, even for these very early 
stage patients is combined chemoradiation. 
When mesothelioma is removed surgically, an attempt is made to 
remove the entire pleural surface of the affected lung and the chest wall 
(pleurectomy- PL). Surgery that involves the removal of the ipsilateral 
pleura, the ipsilateral diaphragm and pericardium, the entire involved 
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lung, and frequently part of the chest wall is called extra-pleural 
pneumonectomy (EPP) (Figure 25). 
 
Figure 25. Right Pneumonectomy. Illustration by Sarah Alyssa Uy. 
The current standard method of attempting cure for mesothelioma 
involves administering chemotherapy first to eliminate possible 
metastases (neoadjuvant chemotherapy), EPP to remove the bulk of the 
tumor, and post-operative radiation to the ipsilateral hemithorax to 
attempt to eradicate residual disease. Many patients with mesothelioma 
do not have the cardiopulmonary reserve to tolerate an EPP, and even 
after undergoing this treatment regimen the recurrence rate is still high. 
However, not every person with early stage non-small cell disease is 
medically able to withstand a major thoracotomy or the loss of lung 
parenchyma. Therefore cardiopulmonary and other medical assessment 
is appropriate before embarking on such major procedures. Pulmonary 
function tests are performed on major lung resection candidates, and 
predict the probability of major postoperative pulmonary-related 
complications. Regardless of the type of lung resection done (lobectomy, 
pneumonectomy etc.), patients should have at least 40% of their ideal 
FEV1 (forced expiratory volume in 1 second) and DLCO (diffusion 
capacity for carbon monoxide) left at the end of their lung surgery. Since 
major lung resections are quite stressful on the heart because of the 
acute increase in pulmonary vascular resistance which accompanies 
lung removal, in selected patients a cardiac evaluation in the form of 
either an exercise or pharmacologic cardiac stress test is done. 
Some people decide they do not want surgery. It is not yet known to 
what degree patients may still be cured if they medically cannot tolerate 
or choose not to undergo an operation but receive other types of 
treatments, such as newer radiation therapy techniques that focally 
target the tumor with high doses (Movie 2). Even if such people cannot 
achieve a cure of their cancer, they may enjoy long term survival. 
Chemotherapy 
For localized small cell carcinoma, clinical studies over the years have 
shown that there is an improvement in clinical outcome, including 
survival, if limited stage small cell lung cancer is treated with a 
combination of chemotherapy and radiation therapy. This therapy needs 
to start as rapidly as possible. 
When a non-small cell lung cancer has spread to nearby lymph nodes or 
has spread to other nearby anatomic structures (such as the chest wall) 
but has not overtly been found to have metastasized elsewhere, 
chemotherapy with radiation therapy can be used initially to treat the 
cancer. This is called neoadjuvant treatment. Some patients whose 
tumors respond well to concurrent chemotherapy and thoracic radiation 
may be candidates for thoracic surgery to remove any residual cancer. 
As the cancer becomes bulky, such neoadjuvant treatment is less and 
less successful. 
When either non-small cell or small cell cancers have spread to distant 
sites (metastatic, or Stage IV disease), then the foundation of treatment 
is systemic chemotherapy. The goal of such treatment is palliative, not 
curative. Randomized trials have shown about a six to eight-month 
improvement in median overall survival with the use of current 
chemotherapy in metastatic lung cancer compared to no anti-cancer 
treatment. However, patients who respond to treatment can enjoy 
significant relief of symptoms caused by the cancer, such as pain, 
fatigue, shortness of breath, loss of appetite, and weight loss. It has 
recently been documented that early involvement of a palliative care 
service in the care of patients with advanced lung cancer can extend 
survival as well as enhance quality of life. 
A small percentage of patients with non-small cell lung cancer, 
particularly with adenocarcinoma, may have a specific acquired gene 
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mutation in their cancer that can serve as a target for therapy. Mutations 
in the epidermal growth factor receptor (EGFR) gene can cause 
activation of the EGFR tyrosine kinase (TK). Erlotinib and gefitinib are 
inhibitors of the EGFR TK and treatment with these drugs, will produce a 
tumor response in 75% of these patients. Similarly, the fusion gene, 
echinoderm microtubule-associated protein-like 4 anaplastic lymphoma 
kinase (EML4-ALK) results in activation of the ALK oncogene. Crizotinib 
is a specific inhibitor of ALK TK and can produce a tumor response in 
about 60% of patients whose tumors have the EML-ALK fusion gene. 
Recently the antibodies nivolumab and pembrolizumab have been 
approved for treatment of recurrent metastatic non-small cell lung cancer 
after previous treatment with chemotherapy. These antibodies target the 
programmed death 1 (PD-1) receptor on T cells. PD-1 activation is one 
mechanism used by the immune system to down regulate an immune 
response. Anti-PD-1 antibodies are able to block this immune checkpoint 
and represent a novel immune therapy of lung cancer. It is anticipated 
that the use of these antibodies, and others that work via a similar 
mechanism, will increase significantly in the near future. 
Radiation Therapy (RT) 
Radiation therapy is regional treatment, used to treat the primary and 
draining lymphatic volumes, with curative intent (as primary treatment, 
hoping to achieve long term control), as neoadjuvant or adjuvant therapy 
(in each case, with or without sensitizing chemotherapy), with 
prophylactic intent or with palliative intent.  
Recently, stereotactic radiation therapy (2-5 treatments) or radiosurgery 
(a single treatment) has been used in an attempt to ablate small tumors 















Movie 2. Stereotactic radiation treatment of a small lung cancer. Movie courtesy 
of the University of Massachusetts, Department of Radiation Oncology. 
In addition, fractionated radiation therapy is often utilized in an attempt to 
prevent the development of brain metastases in patients with small cell 
carcinoma, referred to as prophylactic cranial irradiation (PCI). 
In the palliative treatment of advanced stages of lung cancer and 
mesothelioma, radiation therapy may be used to target a painful bone 
metastasis or to help keep open a lung airway that is becoming 
obstructed or compressed by the cancer. It is important to remember that 
when a patient reaches a point in the course of cancer that anti-cancer 
treatment is no longer possible, the responsibility to still care for the 
person remains. In particular, hemoptysis is effectively and quickly 
reduced or eliminated in patients receiving palliative radiotherapy. 
Conclusion 
Management of all forms of lung cancer and of mesothelioma requires a 
multidisciplinary approach to care involving Medical Oncologists, 
Radiation Oncologists, Thoracic Surgeons, Pulmonologists, Palliative 
Care Physicians, Pathologists, Radiologists, and Primary Care 
Physicians. 
Prevention is the most effective means of decreasing mortality from 
these diseases; this requires protection from exposure to asbestos and 
tobacco. 
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Thought Questions 
1. If cigarette smoking magically disappears tomorrow, what impact 
would you expect that to have on lung cancer incidence? Would lung 





















2. Why is it important to distinguish between small cell and non-small 
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3. Why is it less important to distinguish between the various histologic 


























4. How could molecular profiling of cancers affect the clinical 
importance of distinguishing between the different kinds of non-small 
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5. Why has the incidence of undifferentiated large cell carcinoma 
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Glossary 
Bulky disease- Large volume of cancer in primary nodes or metastatic 
sites. Bulky disease in Hodgkin disease is defined differently. 
Effusion- Fluid in pericardial sac or pleural space 
Metastasize- Spread to distant parts of the body 
Other tobacco-related problems- Coronary heart disease, chronic 
obstructive pulmonary disease (COPD), diabetes mellitus, peripheral 
vascular disease, emphysema, and central nervous problems (such as 
strokes) 
Packs per day- Amount of cigarette use at any individual time 
Pack years- Cumulative duration of cigarette use. (Maximum number of 
packs per day) x (Number of years smoking) 
Thoracotomy- Surgical operation of cutting through the chest wall into 
the pleural space 
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Staging Diagrams 
AJCC staging consists of the disease (cancer site/type), the type of staging or timing of the 
staging: clinical (c) versus pathologic (p) versus post-neoadjuvant therapy (yp), the stage group (I-
IV) and the T (primary site), N (nodal involvement), and M (metastasis) stage categories.  
Oncologists draw tumor deposits on outlines of body regions, usually with red ink, during the 
staging of a cancer. The process of drawing helps physicians remember the patient’s stage; 
drawing a series of stages for a given disease site helps learn the staging system, and makes the 
AJCC staging table meaningful for visual learners. 
In this packet are: 
1. Blank staging diagrams to assist with staging the patients you see. Printing out these blank 
diagrams and staging patients on the diagrams would be a valuable exercise. 
2. Case-based interactive staging diagrams to provide a self-assessment of your staging 
knowledge. A patient’s extent of disease is described in each case. Write the Type of 
Staging, Stage Group, T stage, N stage, and M stage in the corresponding blank fields. 
Clicking on the Expert Answers and Diagrams link will trigger the correct stage and 
annotated diagram to appear. 
The blank diagrams below were created using a CT image set on the Varian Aria Radiation 
Therapy Treatment Planning System. Images Courtesy of University of Massachusetts Medical 
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Blank Staging Diagram Form for Thoracic Malignancies 
 
AJCC Lung Cancer Staging, 7th Edition is available here. 
 
Disease: Thoracic Malignancy 
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Interactive Staging Diagram Form for Thoracic Malignancies 
 
 
A1. Chest radiograph demonstrates a 2 cm mass in right upper lung field. Brain MRI is negative, 
and PET/CT scan shows a 1.4 cm mass in the right upper lobe, which is PET avid, but no 
other evidence of PET uptake.  
 
Disease: Lung Cancer 










Click here to reveal Expert 
Answers and annotated diagram 
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A2. After thoracotomy on the patient described in A1, pathology report shows 1.6 cm nodule of 
squamous cell carcinoma and 12 negative lymph nodes. 
 
Disease: Lung Cancer 








Click here to reveal Expert 
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B. After chemotherapy for biopsy proven adenocarcinoma of the right lower lobe of the lung, CT shows 6 
cm mass in right lower lung; & right hilar mass which is negative on PET scan. PET/CT and Brain MRI 
show no evidence of spread beyond the chest. So resection proceeds. Both masses seen are resected; 
both contain tumor. 
 
Disease: Lung Cancer 












Click here to reveal Expert 
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C. 8 cm mass in right lower lung, ipsilateral paratracheal and hilar nodes and needle biopsy of level 7 
(subcarinal) node read as small cell carcinoma. Brain MRI is negative, and PET/CT shows no evidence 
of disease outside the thorax.  
 
Disease: Lung Cancer 












Click here to reveal Expert 
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D. 2 cm mass in right lower lobe; needle biopsy of contralateral paratracheal mass performed under 
endobronchial ultrasonic guidance read as consistent with carcinoma, consistent with squamous cell 
carcinoma. Brain MRI is negative, and PET/CT shows no evidence of disease outside the thorax. 
 
Disease: Lung Cancer 












Click here to reveal Expert 
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E. Screening CT shows a new 2.5 cm right lower lobe nodule and bilateral supraclavicular 
masses; the left one, Virchow’s node, is palpable and needle biopsy of this mass was read as 
malignant cells consistent with adenocarcinoma. 
 
Disease: Lung Cancer 
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F. Screening CT of a heavy smoker reveals a 1 cm mass in the left upper lobe of the lung, and an 
enlarged adrenal gland, consistent with metastasis. Needle biopsy of the adrenal gland read as 
small cell carcinoma. Brain MRI demonstrates many small enhancing lesions in the brain; the 
largest is the cerebellum, with surrounding edema. And bone scan is positive in the right 
scapula. 
 
Disease: Lung Cancer 













Click here to reveal Expert 
Answers and annotated 
diagram 
